Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by rebiject autoinjection over a 1-year period: The CoSa study

Clinical Neuropharmacology

Volumn 31, Issue 3, 2008, Pages 167-172

  Lugaresi, Alessandra ^a,j   Durastanti, Valentina ^b   Gasperini, Claudio ^c   Lai, Marina ^d   Pozzilli, Carlo ^e   Orefice, Giuseppe ^f   Sotgiu, Stefano ^g   Pucci, Emilio ^h   Ardito, Bruno ⁱ   Millefiorini, Enrico ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g UNIVERSITY OF SASSARI   (Italy)

^h Macerata Hospital   (Italy)

ⁱ MIULLI GENERAL HOSPITAL   (Italy)

^j Ospedale SS Annunziata   (Italy)

more..

Author keywords

Autoinjection system; Interferon beta; Multiple sclerosis; Patient satisfaction; Rebiject

Indexed keywords

BETA1A INTERFERON; GLATIRAMER;

ADULT; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; HUMAN; INJECTION SITE REACTION; INJURY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PAIN; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE; RELAPSE; SELF INJECTION; SKIN MANIFESTATION;

ADJUVANTS, IMMUNOLOGIC; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUESTIONNAIRES; RECURRENCE; SELF ADMINISTRATION; SEVERITY OF ILLNESS INDEX; SYRINGES; TREATMENT OUTCOME;

EID: 44649107724     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/wnf.0b013e3181571a8e     Document Type: Article

References (17)

1. IFNb Multiple Sclerosis Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294.
3. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-1504.
4. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Ann Neurol 1999;46:197-206.
5. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-1636.
6. Murdoch D, Lyseng-Williamson KA. Subcutaneous recombinant interferon-β-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis. Drugs 2005;65:1295-1312.
7. Weidmann E, Unger J, Blair S, et al. An open-label study to assess changes in efficacy and satisfaction with migraine care when patients have access to multiple sumatriptan succinate formulations. Clin Ther 2003;25:235-246.
8. Weaver M, Patrick DL, Markson LE, et al. Issues in the measurement of satisfaction with treatment. Am J Manag Care 1997;3:579-594.
9. Sandberg-Wollheim M, Bever C, Carter J, et al. Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study. J Neurol 2005;252:8-13.
10. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002;59:1496-1506.
11. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-178.
12. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
13. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-911.
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
15. Cramer JA, Cuffel BJ, Divan V, et al. Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurol Scand 2006;113:156-162.
16. Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care 2004;27:2495-2497.
17. Green J, Kleinman L, Ciesla G, et al. Subcutaneous injection survey: psychometric evaluation of a treatment satisfaction instrument associated with a novel HIV medication. HIV Clin Trials 2002;3:387-395.